ProCE Banner Activity

Panobinostat/Carfilzomib With Promising Activity in R/R Multiple Myeloma

Slideset Download
Conference Coverage
In this continuation of a phase I/II trial, the optimized dose and schedule of panobinostat and carfilzomib was associated with promising responses in relapsed/refractory multiple myeloma.

Released: June 05, 2015

Expiration: June 03, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation